Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Atracurium Besylate Injection Generic Name & Formulations
Legal Class
Rx
General Description
Atracurium besylate 10mg/mL; soln for IV inj.
Pharmacological Class
Neuromuscular blocker (nondepolarizing).
How Supplied
Contact supplier.
Manufacturer
Atracurium Besylate Injection Indications
Indications
Adjunct to general anesthesia to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Atracurium Besylate Injection Dosage and Administration
Adults and Children
<1month: not recommended. Individualize. 1month to 2yrs (under halothane anesthesia): initially 0.3–0.4mg/kg. ≥2yrs: initially 0.4–0.5mg/kg IV bolus. Inhalation anesthetics (eg, enflurane, isoflurane): 0.25–0.35mg/kg. Prolonged surgery: maintenance dose of 0.08–0.10mg/kg, usually given 20–45 minutes after initial inj dose. Intubation with succinylcholine, significant cardiovascular disease, history of severe anaphylaxis or asthma: initially 0.3–0.4mg/kg given slowly or in divided doses over 1 minute. Neuromuscular disease, severe electrolyte disorders, or carcinomatosis: consider dose reductions. Use by continuous infusion: see literature. Monitor with a peripheral nerve stimulator to avoid overdosage.
Atracurium Besylate Injection Contraindications
Contraindications
Hypersensitivity to benzyl alcohol (multidose vials).
Atracurium Besylate Injection Boxed Warnings
Not Applicable
Atracurium Besylate Injection Warnings/Precautions
Warnings/Precautions
To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Not for IM administration. Increased risk of substantial histamine release (eg, cardiovascular disease, severe anaphylaxis or asthma history). Myasthenia gravis or myasthenic (Eaton-Lambert) syndrome. Severe electrolyte disorders or carcinomatosis. Malignant hyperthermia. Resistance may develop in burn patients. Bronchial asthma. Long-term use in I.C.U. Neonates. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Atracurium Besylate Injection Pharmacokinetics
See Literature
Atracurium Besylate Injection Interactions
Interactions
Prior administration of succinylcholine may potentiate effects (give atracurium only after succinylcholine recovery). Potentiated by volatile inhalational anesthetics (eg, enflurane, isoflurane, halothane), aminoglycosides, polymyxins, lithium, magnesium salts, procainamide, quinidine. Concomitant other muscle relaxants may have synergistic or antagonistic effects.
Atracurium Besylate Injection Adverse Reactions
Adverse Reactions
Skin flushing, erythema, tachycardia, inadequate or prolonged musculoskeletal block, hypotension, bradycardia, dyspnea; rare: seizures, severe hypersensitivity reactions.
Atracurium Besylate Injection Clinical Trials
See Literature
Atracurium Besylate Injection Note
Notes
Formerly known under the brand name Tracrium.
Atracurium Besylate Injection Patient Counseling
See Literature
